Angina Pectoris Drugs Industry Insights Technology and Dynamics Forecast To 2022
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Angina</strong> <strong>Pectoris</strong> <strong>Drugs</strong> <strong>Industry</strong> <strong>Insights</strong> | <strong>Technology</strong> <strong>and</strong><br />
<strong>Dynamics</strong> | <strong>Forecast</strong> <strong>To</strong> <strong>2022</strong><br />
“Global <strong>Angina</strong> <strong>Pectoris</strong> <strong>Drugs</strong> Market report includes in-depth analysis of<br />
industry by recent technologies, trends, opportunities, challenges, key players<br />
<strong>and</strong> business strategies considering types, segment <strong>and</strong> future outlook.”<br />
Global <strong>Angina</strong> <strong>Pectoris</strong> <strong>Drugs</strong> Market is estimated to reach USD 10.6 billion by <strong>2022</strong> owing to<br />
the rising number of patients suffering from angina pectoris <strong>and</strong> the probable acceptance of<br />
modern therapies like varespladib <strong>and</strong> Generx that are in late stage of clinical development. If<br />
these modern therapies are approved, they are expected to contribute impressively to the<br />
growth of angina pectoris drugs industry since they will be sold at premium prices by<br />
manufacturing companies.<br />
When chest pain (angina) occurs, physicians suggest blockages in heart arteries. There are many<br />
types of angina one may have, but the major ones are chronic stable angina that occurs when<br />
the heart is working steadily <strong>and</strong> the unstable angina which occurs when the chest pain gets<br />
worse. The other types comprise variant angina <strong>and</strong> microvascular angina. At present, angina<br />
pectoris treatments are not comparatively effective <strong>and</strong> therefore newbies are experiencing<br />
new opportunities to introduce more effective therapies <strong>and</strong> contribute the growth of angina<br />
pectoris drugs market. The rise in chronic diseases is one of the major growth factors for the<br />
growth of angina pectoris drugs industry. <strong>Angina</strong> <strong>Pectoris</strong> is mainly caused by growing<br />
prevalence of chronic diseases like high blood pressure, diabetes <strong>and</strong> obesity.<br />
Request Sample Copy of this Market Research @ https://www.millioninsights.com/industryreports/angina-pectoris-drugs-market/request-sample
High blood pressure <strong>and</strong> diabetes are likely to develop more serious health issues associated<br />
with numerous important organs. Obesity is the main reason for fatal cardiac disorders<br />
irrespective of the person is suffering from high blood pressure or diabetes. The increasing<br />
geriatric population is also projected to encourage the dem<strong>and</strong> for angina pectoris drugs in the<br />
forecast period.<br />
(β-blockers) β-Adrenoceptor antagonists are suggested for the first line treatment of heart<br />
failure, arterial fibrillation, coronary artery disease <strong>and</strong> hypertension with heart failure, angina<br />
pectoris, or prior myocardial infarction. β-Blocker therapy is also used in asymptomatic patients<br />
with large areas of ischemia (level IIa C evidence) <strong>and</strong> in microvascular angina to recover effortrelated<br />
angina symptoms. A research revealed that chronic stable angina affects very less<br />
population in the western countries with an anticipated yearly risk of death <strong>and</strong> non-fatal<br />
myocardial infraction of comparatively less population.<br />
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market<br />
<strong>Angina</strong> pectoris drugs market is categorized on the basis of drug class, end-users, <strong>and</strong><br />
geography. On the basis of drug class, the market is divided into Angiotensin-converting enzyme<br />
inhibitors, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting<br />
Nitroglycerines, Anti-ischemic agents <strong>and</strong> Antiplatelet agents. In terms of end-users, angina<br />
pectoris drugs industry is segmented as retail pharmacies, hospital pharmacies <strong>and</strong> online<br />
pharmacies.<br />
Geographically, angina pectoris drugs market is segmented as Asia Pacific, North America,<br />
Europe, South America, <strong>and</strong> Middle East & Africa. North America is expected to dominate the<br />
market owing to high prevalence of chronic disorders <strong>and</strong> improved healthcare infrastructure.<br />
The prominent players in angina pectoris drugs industry comprise Astellas Pharma, AstraZeneca<br />
PLC, Ark Therapeutics Group plc, Cardium Therapeutics, Cardeus Pharmaceuticals,<br />
CardioVascularBioTherapeutics (CVBT), HUYA Bioscience International LLC, Bristol-Myers<br />
Squibb Company, F. Hoffmann-La Roche Ltd, Korea Otsuka Pharmaceutical Co.Ltd, Pfizer, Inc.,<br />
Baxalta US Inc., Gilead Sciences, Inc, Sanofi SA, <strong>and</strong> TSH Biopharm Corporation Limited.<br />
Market Segment:
Therapeutic Class Outlook (% market share; 2016 - <strong>2022</strong>)<br />
• Beta Blockers<br />
• Calcium Antagonists<br />
• Anticoagulants<br />
• Anti-Platelets<br />
• Others<br />
• Nitrates<br />
• Anti-anginal (Ranolazine)<br />
• ACE inhibitors<br />
Regional Outlook (% market share; 2016 - <strong>2022</strong>)<br />
• U.S.<br />
• U.K.<br />
• France<br />
• Germany<br />
• Italy<br />
• Spain<br />
• Japan<br />
See More Reports of this Category by Million <strong>Insights</strong> @<br />
https://www.millioninsights.com/industry/pharmaceuticals
Get in touch<br />
At Million <strong>Insights</strong>, we work with the aim to reach the highest levels of customer satisfaction. Our<br />
representatives strive to underst<strong>and</strong> diverse client requirements <strong>and</strong> cater to the same with the<br />
most innovative <strong>and</strong> functional solutions.<br />
Contact Person:<br />
Ryan Manuel<br />
Research Support Specialist, USA<br />
Email: ryan@millioninsights.com<br />
Global Headquarters<br />
Million <strong>Insights</strong><br />
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States<br />
Phone: 1-408-610-2300<br />
Email: sales@millioninsights.com<br />
Asia Pacific<br />
Million <strong>Insights</strong><br />
Office No. 302, 3rd Floor, Manikch<strong>and</strong> Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016<br />
India<br />
Phone: 91-20-65300184
Change language